Table 1.
Selected ICB trials demonstrating high efficacy for MMRd CRC and other TMB-high tumors.
| Drug/phase | Cancer | Response | Ref |
|---|---|---|---|
| Pembrolizumab small phase 2 (2015) | MMRd CRC | Response rate: 40% Progression free survival rate: 78% |
(33) |
| MMRp CRC | Response rate: 0% Progression free survival rate: 11% |
(33) | |
| MMRd non-CRC | Response rate: 40% Progression free survival rate: 78% |
(33) | |
| Pembrolizumab phase 2 (2018) | MMRd CRC and non-CRC | Objective radiographic responses: 53% Complete responses: 21% |
(34) |
| Nivolumab plus Ipilimumab phase 2 (2018) | MMRd CRC | Overall response rate: 55% | (37) |
| Pembrolizumab vs chemotherapy phase 3 (2020) | MMRd metastatic CRC | Complete or partial response: 43.8% vs 33.1% No difference in overall survival Grade 3 and 4 adverse events: 22% vs 66% |
(35) |
| Dostarlimab neoadjuvant (2022) | MMRd stage II or III rectal adenocarcinoma | Complete response: 100% (only 12 patients) | (44) |
| Ipilimumab plus Pembrolizumab or Nivolumab vs Ipilimumab (2021) | Metastatic melanoma | Objective response rate: 31% vs 13% Median overall survival: 20.4 months vs 8.8 months |
(40) |
| Pembrolizumab vs chemotherapy (2019) | NSCLC | Overall response rate: 45% vs 28% | (41) |